Navigation Links
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. Arena is finishing a complete analysis of the data, but does not anticipate any further development of APD125.

"While we are disappointed and anticipated a different result based on objective polysomnographic results from our previous studies, our priority remains the successful development of lorcaserin, our proprietary investigative treatment for obesity. We expect to announce lorcaserin results from BLOOM, our first pivotal Phase 3 clinical trial, around the end of March and to file a New Drug Application for lorcaserin by the end of 2009," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the opportunity to review our lorcaserin program, as well as other programs, at our upcoming R&D Day on December 15."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Critical Pharmaceuticals Enter Sustained Release hGH Arena
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
8. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- The Galien Foundation today announced the 2014 nominees ... Awards. The Prix Galien Award is considered ... scientific and clinical research skills necessary to develop innovative ... highest number of nominees since the inception of the ... biomedical products across three categories – biotechnology, pharmaceutical, and ...
(Date:7/31/2014)... Cryoport, Inc. (OTCBB: CYRX) today announced financial results for ... Recent Operating Highlights , Achieved 92% ... period ended June 30, 2014 compared to the prior ... expand Cryoport,s global reach using the ,powered by Cryoport ... an immunotherapy and vaccine development services company, to support ...
(Date:7/31/2014)... , July 31, 2014  Genomic Health, Inc. (Nasdaq: ... a conference call and webcast on Thursday, August 7 at ... financial results.  The call and webcast will follow the release ... Conference Call Details To access the live conference call ... please dial (877) 303-7208 from the United States ...
Breaking Medicine Technology:The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4
... Report Issued to Improve Policies Affecting How Human ... At the same time,that medical science is making ... once fatal diseases, a new report finds major,shortcomings ... out and,funded in the U.S. with serious implications ...
... Belgium, April 1 , - Trial Results Expected ... company,focused on vascular diseases, eye diseases and cancer, today ... IIb MIVI III trial in the,United States. This study ... in vitrectomy (MIVI III - Microplasmin for Vitreous,Injection)., ...
Cached Medicine Technology:Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 2Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 3Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 4Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 5Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 6Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation 7ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 2ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 3ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III) 4
(Date:8/1/2014)... Blindness is a reversible ailment these ... of today, despite well-meaning efforts, still have a long way ... for reversing blindness that does not involve any kind of ... alternative medicine takes the “slack” from the mainstream by providing ... harmful surgeries. , Alternative health specialist Kevin Richardson actually ...
(Date:8/1/2014)... Cypress, CA (PRWEB) August 01, 2014 ... to advancing gynecologic endoscopic surgery, is pleased to ... societies, in the United States and Europe, which ... make available to surgeons an endoscopic dry lab ... proficiency of their endoscopic surgery skills. , Endoscopy ...
(Date:8/1/2014)... August 01, 2014 Surftech athletes Jack ... Oahu paddleboard World Championships this past weekend in Hawaii ... 3rd place finisher Zeb Walsh were all on stock ... of the race and athletes this year were treated ... making the course extremely challenging as well as very ...
(Date:8/1/2014)... iFitDress.com, a professional company of women’s dresses ... 2014 silver bridesmaid dresses recently. All of ... latest fashion trends. What’s more, they are now offered ... , iFitDress.com is one of the leading suppliers ... silver bridesmaid gowns, but also many other kinds of ...
(Date:7/31/2014)... Women over the age of 65 face numerous ... greater struggles against poverty and higher rates of asthma ... August issue of Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), outlines the challenges ... practical solutions to improve their care. , ...
Breaking Medicine News(10 mins):Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:AAGL Announces It Has Joined With Other Medical Societies to Encourage Hospitals Teaching Endoscopic Surgery to Establish Simulator Labs for Training 2Health News:Surftech Bark Commander Sweeps Molokai2Oahu Stock Paddleboard Division 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3
... Coalition of patients, practitioners and employers urges ... deployment of interoperable health,information technology, WASHINGTON, ... co-chaired by former Senator John Breaux and ... Eshoo,and Mike Rogers for introducing legislation that ...
... The Pennsylvania,Department of Health today is emphasizing ... for consumers not to eat Banquet brand and,store ... possible,Salmonella contamination., "Federal officials have already shared ... ensure Pennsylvanians are taking the,appropriate measures to protect ...
... Guttmacher,Institute,s latest report on world abortion rates is ... W. Mosher. The,study, just released today, argues that ... developing countries., Accurate numbers are impossible to ... illegal. Says Mosher: "Neither,Guttmacher nor anyone else knows ...
... have discovered a key protein that controls how stem ... move limbs, or smooth muscle cells that support blood ... Proceedings of the National Academy of Sciences (PNAS). ... of muscle types in the human fetus, but also ...
... Ohio, Oct. 10 PartsSource, the nation,s leading,supplier ... &,CEO, A. Ray Dalton has been selected as ... Business" award. This honor is given to,executives who ... new,businesses throughout their professional career. "I am ...
... ... geographically, WILMINGTON, N.C., Oct. 10 ... as senior vice,president of clinical operations for North America and Simon ... Colvin joins PPD from Eli Lilly and Company where he most ...
Cached Medicine News:Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:PRI Criticizes Guttmacher Report 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5Health News:PPD Names VPs for North America and Asia 2Health News:PPD Names VPs for North America and Asia 3
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... A & B Test simplifies rapid ... on the market just got easier ... and influenza B using one simple ... can focus on the results and ...
... Combo with Reference Line Test ... human chorionic gonadotropin (hCG) in ... test kit is used to ... is intended for professional and ...
... Experience the finest surgical-quality loupes ... set the standard for innovative optical ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. Make ...
Medicine Products: